Angiotensin-(1-7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: Role of the AT1 and Mas receptors

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 2, 2007, Pages

  Giani, Jorge F ^a   Gironacci, Mariela M ^a   Muñoz, Marina C ^a   Peña, Clara ^a   Turyn, Daniel ^a   Dominici, Fernando P ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Angiotensin II; Insulin receptor substrate 1; Janus kinase; Signal transduction

Indexed keywords

A 779; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN[1-7]; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; JANUS KINASE 2; LOSARTAN; MAS RECEPTOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEART; HEART CONTRACTION; HYPERTENSION; IN VIVO STUDY; INHIBITION KINETICS; INSULIN RESISTANCE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STIMULATION;

EID: 34547924469     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01395.2006     Document Type: Article

References (54)

1. Abel ED. Insulin signaling in heart muscle: lessons from genetically engineered mouse models. Curr Hypertens Rep 6: 416-423, 2004.
2. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551, 1996.
3. Argentino DP, Dominici FP, Al-Regaiey K, Bonkowski MS, Bartke A, Turyn D. Effects of long-term caloric restriction on early steps of the insulin signaling system in the Mouse Skeletal Muscle. J Gerontol A Biol Sci Med Sci 60: 28-34, 2005.
4. Bradley EA, Clark MG, Rattigan S. Acute effects of wortmannin on insulin's hemodynamic and metabolic actions in vivo. Am J Physiol Endocrinol Metab 292: E779-E787, 2007.
5. Calegari VC, Alves M, Picardi PK, Inoue RY, Franchini KG, Saad MJ, Velloso LA. Suppressor of cytokine signaling-3 Provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 146: 579-588, 2005.
6. Campagnole-Santos MJ, Diz DI, Santos RA, Khosla MC, Brosnihan KB, Ferrario CM. Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol Heart Circ Physiol 257: H324-H329, 1989.
7. Carvalheira JB, Calegari VC, Zecchin HG, Nadruz W Jr, Guimaraes RB, Ribeiro EB, Franchini KG, Velloso LA, Saad MJ. The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. Endocrinology 144: 5604-5614, 2003.
8. Carvalho CR, Thirone AC, Gontijo JA, Velloso LA, Saad MJ. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46: 1950-1957, 1997.
9. Carvalho DS, Villaca V, Brenelli SL, Carvalho CR, Saad MJ. Angiotensin-converting enzyme inhibitor increases insulin-induced pp185 phosphorylation in liver and muscle of obese rats. Biochem Mol Biol Int 46: 259-266, 1998.
10. Cui TX, Nakagami H, Nahmias C, Shiuchi T, Takeda-Matsubara Y, Li JM, WuL, Iwai M, Horiuchi M. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol 16: 2113-2123, 2002.
11. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991.
12. Dominici FP, Argentino DP, Muñoz MC, Miquet JG, Sotelo AI, Turyn D. Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 15: 324-336, 2005.
13. Dominici FP, Cifone D, Bartke A, Turyn D. Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice. Am J Physiol Endocrinol Metab 277: E447-E454, 1999.
14. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997.
15. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290, 2005.
16. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7). An evolving story in cardiovascular regulation. Hypertension 47: 515-521, 2006.
17. Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 38: 665-668, 2001.
18. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100: 2158-2169, 1997.
19. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 107: 133-139, 1999.
20. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K, Nakao K. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 576: 492-497, 2004.
21. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22: 1977-1982, 2004.
22. 3H] norepinephrine from rat atria. Hypertension 24: 457-460, 1994.
23. Gironacci MM, Coba MP, Peña C. Angiotensin-(1-7) binds at the type 1 angiotensin II receptors in rat renal cortex. Regul Pept 84: 51-54, 1999.
24. Gironacci MM, Valera MS, Yujnovsky I, Peña C. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension 44: 783-787, 2004.
25. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884-890, 2001.
26. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31: 356-361, 1998.
27. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23: 463-473, 2005.
28. Johnston JA, Wang LM, Hanson EP, Sun XJ, White MF, Oakes SA, Pierce JH, O'Shea JJ. Interleukins 2, 4, 7, and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases. J Biol Chem 270: 28527-28530, 1995.
29. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111: 1806-1813, 2005.
30. Kudoh A, Matsuki A. Effects of angiotensin-converting enzyme inhibitors on glucose uptake. Hypertension 36: 239-244, 2000.
31. Loot AE, Roks AJM, Henning RH, Tio RA, Suurmeijer AJH, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105:1548-1550, 2002.
32. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375: 247-250, 1995.
33. Matsui T, Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 38: 63-71, 2005.
34. Muñoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE. Irbersartan restores the in vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 24: 1607-1617, 2006.
35. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40: 872-879, 2002.
36. Paula RD, Lima CV, Khosla MC, Santos RA. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 26: 1154-1159, 1995.
37. Potts PD, Horiuchi J, Coleman MJ, Dampney RA. The cardiovascular effects of angiotensin-(1-7) in the rostral and caudal ventrolateral medulla of the rabbit. Brain Res 877: 58-64, 2000.
38. Rao RH. Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 7: 655-660, 1994.
39. Richey JM, Ader M, Moore D, Bergman RN. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol Endocrinol Metab 277: E920-E926, 1999.
40. Rowe BP, Saylor DL, Speth RC, Absher DR. Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. Regul Pept 56: 139-146, 1995.
41. Saad MJ, Velloso LA, Carvalho CR. Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J 310: 741-744, 1995.
42. Saad MJA, Carvalho CRO, Thirone ACP, Velloso LA. Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat. J Biol Chem 271: 22100-22104, 1996.
43. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49: 185-192, 2007.
44. Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 14: 1019-1031, 2005.
45. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258-8263, 2003.
46. Schiavone MT, Santos RAS, Brosnihan B, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamus-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci USA 85: 4095-4098, 1988.
47. Shiojima I, Yefremashvili M, Luo Z, Kureishi Y, Takahashi A, Tao J, Rosenzweig A, Kahn CR, Abel ED, Walsh K. Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem 277: 37670-37677, 2002.
48. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-1010, 2004.
49. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286: H1597-H1602, 2004.
50. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96, 2006.
51. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 22: 98-107, 2006.
52. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93: 12490-12495, 1996.
53. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45: 960-966, 2005.
54. White MF. Insulin signaling in health and disease. Science 302: 1710-1711, 2003.